Asset
OMEGA-3-PENTAENOIC ACIDS
MATINAS BIOPHARMA HOLDINGS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04177680 | phase2 | completed | 2020-06-03 | 2020-11-27 | Matinas BioPharma Nanotechnologies, Inc. | Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia |
| NCT04662528 | phase3 | withdrawn | 2021-06-01 | 2022-08-01 | Matinas Biopharma, Inc | Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL |
FDA applications (0)
This company has no applications containing this asset.